Company news
Marvel Biosciences Corp news in 2025
Marvel Biosciences Corp's news releases, calls and decks from 2025, newest first.
Marvel Biosciences Announces Grant of Deferred Share Units
November 10, 2025
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
October 3, 2025
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
August 18, 2025
Marvel Biosciences Announces Closing of Private Placement
May 12, 2025
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
May 2, 2025
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
April 30, 2025
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
April 16, 2025
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
April 14, 2025
Marvel Biosciences Announces Private Placement
March 28, 2025
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
March 17, 2025
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
March 13, 2025
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
March 11, 2025
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
January 16, 2025
Marvel Biosciences Announces Private Placement for up to $2.5 Million
January 7, 2025